The Comanagement Plan: Elevating Retinal Care Through Unified Vision

DISCLOSURE POLICY
In accordance with the ACCME/COPE Standards for Integrity and Independence , it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

Sunir J. Garg, MD, FACS, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Coherus. Consultant: American Academy of Ophthalmology, Apellis Pharmaceuticals, Archimedic, Bausch + Lomb, Boehringer Ingelheim, Carl Zeiss Meditec, Merck Manual, and West Pharmaceuticals. Grant/Research Support: American Academy of Ophthalmology, Apellis Pharmaceuticals, Boehringer Ingelheim, Genentech, Kodiak Biosciences, NGM Bio, and Regeneron. Speaker's Bureau: Canadian Ophthalmological Society, Cole Eye Summit, Physicians' Education Resource, and Retina Fellows Forum.

John W. Kitchens, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Alcon, Apellis Pharmaceuticals, Astellas, Bayer, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech, Harrow, Neurotech Pharmaceuticals, Opthea, Outlook, Regeneron, and Vortex. Consultant: Alcon, AbbVie, Apellis Pharmaceuticals, Astellas, Bayer, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech, Harrow, Neurotech Pharmaceuticals, Opthea, Outlook, and Regeneron. Speaker's Bureau: Apellis Pharmaceuticals, Astellas, Bayer, Genentech, and Regeneron. 

Sara LeMay, OD, has had no financial relationships or affiliations with ineligible companies.

Charles C. Wykoff, MD, PhD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, ADARx, Adverum Biotechnologies, Alcon, Alimera Sciences, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis Pharmaceuticals, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, Biocryst, Bionic Vision, Boehringer Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Curacle, Emmecell, Eyebiotech, EyePoint Pharmaceuticals, Frontera, Genentech, InGel, Janssen, Kiora, Kodiak Sciences, Kowa, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Panther, PerceiveBio, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Suzhou Raymon, Sylentis, TCG Crossover, Théa Pharma, Therini, TissueGen, VH401, Vitranu, and Visgenx. Grant/Research Support: 4DMT, AbbVie, Adverum Biotechnologies, AffaMed, Alexion, Alimera Sciences, Allgenesis, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Ascidian, AsclepiX Therapeutics, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Curacle, Eluminex, EyeBiotech, EyePoint Pharmaceuticals, Genentech, IONIS, iRENIX, Janssen, Kalaris, Kodiak Sciences, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Opthea, Outlook Therapeutics, Oxular, Oxurion, Oyster Point, PerceiveBio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, and VH401. 

The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.